Gerd Sutter, Dr. med. vet.

Full Professor and Chair for Virology

Institute for Infectious Diseases and Zoonoses
Department of Veterinary Sciences
Ludwig-Maximilians-Universität München

Veterinärstr. 13, 80539 München; Tel: +49 89 2180 2514
Email: gerd.sutter@lmu.de

Curriculum vitae

1981-1988 Veterinary Medicine, LMU Munich

1988-1990 Dr. med. vet. Doctorate, LMU Munich

1990-1993 Postdoctoral fellow at the Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, USA

1996 Specialist for Vet. Microbiology (board exam)

1999 Habilitation in Virology, LMU Munich

1994-2003 Research group leader, Institute of Molecular Virology, Helmholtz Zentrum München

2003-2009 Director and Professor, Division of Virology, Paul-Ehrlich-Institut, Langen

2009- Full Professor and Chair for Virology, Department of Veterinary Sciences, LMU Munich

Scientific community, honors, awards

1990 Awardee of the German Federal Program (BMBF) on Infectious Disease Research.

Since 1999 Reviewer for DFG, BMBF, NIAID NIH USA, MRC UK, Wellcome Trust UK, INSERM-INRA France.

1998 Virus Group Symposium Lecturer. 140th Meeting Society for General Microbiology, University of Nottingham, UK

2005 Lecturer on "Rational Design of HIV Vaccines and Immunotherapeutics", Nobel Forum Karolinska Institutet, Stockholm, Sweden

2008 Organizer & Chairman, 17th International Poxvirus, Asfivirus and Iridovirus Conference, Grainau, Germany

2009 Member, Editorial Review Boards of "Journal of Virology" and "Virology".

2010 Member, WHO Advisory Group of Independent Experts to review the Smallpox research programme (AGIES).

2020 Recipient, DZIF Prize for Translational Infection Research.

2021 Honorary Doctor of Veterinary Medicine (Dr. med. vet. h.c.), University of Veterinary Medicine Hannover, Germany (2021). In recognition of research and response to SARS-CoV-2 and the COVID-19 pandemic.

Research fields

- Vaccine development with emphasis on vector vaccines based on Modified Vaccinia virus Ankara (MVA).
- Prevention of zoonotic and emerging virus infections, e.g. avian influenza, MERS, SARS, West Nile fever, orthopoxvirus infections.
- Mechanisms of (pox-) viral modulation of the host immune system including evasion of innate and adaptive responses to infection.

Selected publications (out of 190; h-index 63)

Sutter G., Moss B. (1992): Nonreplicating vaccinia vector efficiently expresses recombinant genes. *PNAS USA*, 89, 10847-10851 (first description of recombinant vaccinia virus MVA).

Volz A, Kupke A, Song F, *et al.*, Becker S, **Sutter G*** (2015). Protective efficacy of recombinant Modified Vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. *J Virol*, 89:8651-8656.

Haagmans B*, Brand JVD, Raj V, Volz A, Wohlsein P, Smits S., Schipper D, Bestebroer TM, Okba N., Fux R., Bensaid A, Solanes Foz D., Kuiken T., Baumgärtner W, Segales J, **Sutter G***, Osterhaus ADME* (2016). An orthopox-virus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. *Science*, 351:77-81.

Koch T, Dahlke C, *et al.*, Haagmans B, **Sutter G**, Becker S, Addo MM (2020). Safety and immuno-genicity of an MVA vector vaccine candidate against the Middle East respiratory syndrome: a first-in-human trial. *Lancet Infect Dis*, 20:827-838.

Mühlemann B, Vinner L, et al., **Sutter G**, Smith GL, Drosten C, Fouchier R, Smith D, Willerslev E, Jones TC, Sikora M (2020). Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age. *Science* 369: eaaw 897.

Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, et al., Wendtner CM, Förster R, Haagmans BL, Becker S, **Sutter G***, Volz A (2021). Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. *PNAS USA*; 118(28): e2026207118.

08 April 2022